...
首页> 外文期刊>Intensive care medicine >Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department.
【24h】

Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department.

机译:心源性肺水肿的无创压力支持通气和CPAP:急诊科的多中心随机研究。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Noninvasive pressure support ventilation (NIPSV) and continuous positive airway pressure (CPAP) are both advocated in the treatment of cardiogenic pulmonary edema (CPE); however, the superiority of one technique over the other has not been clearly demonstrated. With regard to its physiological effects, we hypothesized that NIPSV would be better than CPAP in terms of clinical benefit. METHODS: In a prospective, randomized, controlled study performed in four emergency departments, 200 patients were assigned to CPAP (n = 101) or NIPSV (n = 99). Primary outcome was combined events of hospital death and tracheal intubation. Secondary outcomes included resolution time, myocardial infarction rate, and length of hospital stay. Separate analysis was performed in patients with hypercapnia and those with high B-type natriuretic peptide (>500 pg/ml). RESULTS: Hospital death occurred in 5 (5.0%) patients receiving NIPSV and 3 (2.9%) patients receiving CPAP (p = 0.56). The need for intubation was observed in 6 (6%) patients in the NIPSV group and 4 (3.9%) patients in the CPAP group (p = 0.46). Combined events were similar in both groups. NIPSV was associated to a shorter resolution time compared to CPAP (159 +/- 54 vs. 210 +/- 73 min; p < 0.01), whereas the incidence of new myocardial infarction was not different between both groups. Similar results were found in hypercapnic patients and those with high B-type natriuretic peptide. CONCLUSIONS: During CPE, NIPSV accelerates the improvement of respiratory failure compared to CPAP but does not affect primary clinical outcome either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide.
机译:简介:无创压力支持通气(NIPSV)和持续气道正压通气(CPAP)均被推荐用于心源性肺水肿(CPE)的治疗。但是,一种技术相对于另一种技术的优越性尚未得到明确证明。关于其生理效应,我们假设在临床获益方面,NIPSV将比CPAP更好。方法:在四个急诊科中进行的前瞻性,随机对照研究中,将200名患者分配为CPAP(n = 101)或NIPSV(n = 99)。主要结局是医院死亡和气管插管的综合事件。次要结果包括解决时间,心肌梗塞率和住院时间。对高碳酸血症患者和高B型钠尿肽(> 500 pg / ml)的患者进行单独分析。结果:5例(5.0%)接受NIPSV的患者和3例(2.9%)接受CPAP的患者死亡(p = 0.56)。 NIPSV组中有6名(6%)患者和CPAP组中有4名(3.9%)患者观察到需要插管(p = 0.46)。两组的合并事件相似。与CPAP相比,NIPSV的解决时间更短(159 +/- 54比210 +/- 73分钟; p <0.01),而两组之间新发心肌梗死的发生率没有差异。在高碳酸血症患者和高B型利钠肽患者中也发现了类似的结果。结论:在CPE期间,与CPAP相比,NIPSV可以加速呼吸衰竭的改善,但无论是对总体人群还是在高碳酸血症患者或B型利钠肽水平较高的患者亚组中,NIPSV均不影响主要的临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号